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METHODOLOGY
Adhesion of Plasmodium falciparum 
infected erythrocytes in ex vivo perfused 
placental tissue: a novel model of placental 
malaria
Caroline Pehrson1*†, Line Mathiesen2†, Kristine K. Heno1, Ali Salanti1, Mafalda Resende1, Ron Dzikowski3, 
Peter Damm4, Stefan R. Hansson5, Christopher L. King6, Henning Schneider7, Christian W. Wang1, 
Thomas Lavstsen1, Thor G. Theander1, Lisbeth E. Knudsen2 and Morten A. Nielsen1*
Abstract 
Background: Placental malaria occurs when Plasmodium falciparum infected erythrocytes sequester in the placenta. 
Placental parasite isolates bind to chondroitin sulphate A (CSA) by expression of VAR2CSA on the surface of infected 
erythrocytes, but may sequester by other VAR2CSA mediated mechanisms, such as binding to immunoglobulins. 
Furthermore, other parasite antigens have been associated with placental malaria. These findings have important 
implications for placental malaria vaccine design. The objective of this study was to adapt and describe a biologically 
relevant model of parasite adhesion in intact placental tissue.
Results: The ex vivo placental perfusion model was modified to study adhesion of infected erythrocytes binding to 
CSA, endothelial protein C receptor (EPCR) or a transgenic parasite where P. falciparum erythrocyte membrane protein 
1 expression had been shut down. Infected erythrocytes expressing VAR2CSA accumulated in perfused placental 
tissue whereas the EPCR binding and the transgenic parasite did not. Soluble CSA and antibodies specific against 
VAR2CSA inhibited binding of infected erythrocytes.
Conclusion: The ex vivo model provides a novel way of studying receptor-ligand interactions and antibody medi-
ated inhibition of binding in placental malaria.
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Background
Pregnancy-associated malaria is a major cause of mor-
bidity among pregnant women and their offspring 
in Plasmodium falciparum endemic areas. Plasmo-
dium falciparum infected erythrocytes sequester in 
the intervillous space, causing placental malaria. Preg-
nancy-associated malaria is associated with placental 
intervillositis, maternal anemia and low birth-weight 
[1]. Current measures to protect pregnant women from 
pregnancy-associated malaria are insecticide-treated bed 
nets, intermittent preventive treatment in pregnancy and 
treatment of infections [2]. However, pregnancy-associ-
ated malaria is often asymptomatic and may occur before 
the first antenatal visit [3]. Increasing resistance to anti-
parasite and anti-mosquito drugs along with changed 
vector behaviour is reducing efficacy of current protec-
tive measure for pregnant women. Parasites express P. 
falciparum erythrocyte membrane protein 1 (PfEMP1) 
on the surface of infected erythrocytes, mediating 
cytoadhesion to endothelial cells, platelets, erythrocytes 
and syncytiotrophoblast, thereby evading circulation and 
Open Access
Malaria Journal
*Correspondence:  cpeh@sund.ku.dk; mortenn@sund.ku.dk 
†Caroline Pehrson and Line Mathiesen contributed equally to this work
1 Centre for Medical Parasitology at Department of Immunology 
and Microbiology, Faculty of Health and Medical Sciences, University 
of Copenhagen and at Department of Infectious Diseases, Copenhagen 
University Hospital (Rigshospitalet), Copenhagen, Denmark
Full list of author information is available at the end of the article
Page 2 of 12Pehrson et al. Malar J  (2016) 15:292 
destruction in the spleen. VAR2CSA, a unique member 
of the PfEMP1 protein family, was discovered in 2003 
[4], since then a large base of evidence supports the 
causal relationship between VAR2CSA and placental 
malaria [5–12]. Parasites infecting pregnant women bind 
to chondroitin sulfate A (CSA) [13] and recombinant 
VAR2CSA bind with high affinity to CSA [14–16]. How-
ever, binding to immunoglobulin and hyaluronic acid 
have also been associated with placental malaria [17–19]. 
Furthermore, it is not known whether parasites binding 
to receptors other than CSA can accumulate in the pla-
centa as such parasites are restricted by immunity, since 
women in malaria endemic regions develop protective 
antibodies during childhood. Interaction with multiple 
receptors may have implications for how the pathology 
manifests during infections, but also for the development 
of a vaccine to induce antibodies that inhibit the bind-
ing of infected erythrocytes to placental tissue. This is an 
important question in areas of reduced malaria preva-
lence, as less exposure to malaria in childhood may affect 
development of protective immunity, leaving women 
more susceptible to infection when they reach reproduc-
tive age. Currently, adhesion blocking capacity of anti-
bodies has largely been tested in assays where only one 
receptor, namely CSA, is present [20–22], however the 
efficacy of such antibodies may be limited if sequestra-
tion occurs by other pathways. Recent work have shown 
that human placental and cancer cells express a distinct 
form of chondroitin sulfate, that is not present in other 
normal human tissue [23]. Interpretation of binding 
assays using bovine CSA is, therefore, a major concern, 
as VAR2CSA-expressing infected erythrocytes are likely 
to bind with higher affinity to placental CSA. Studies of 
the mechanisms of placental sequestration have used 
placental tissue cryosections, however, these studies are 
contradictory, as they have demonstrated both exclusive 
CSA dependence and involvement of immunoglobulin 
binding [18, 24, 25]. Some of these differences may have 
been incurred by the fixation of tissues that can dam-
age secondary protein structure resulting in alteration of 
important epitopes and/or receptors.
There are established models in which adhesion of 
infected erythrocytes is studied under homogenous flow 
conditions [20, 24]. Although important knowledge of 
parasite adhesion can be derived from these models, they 
do not simulate the complex flow through the villous 
tree in the intervillous space. Modelling of the intervil-
lous blood flow suggests that there is a pressure gradient 
depending on the spacing between spiral artery inflow 
and venous outflow, vessel caliber, and maternal blood 
flow rate [26].
Establishment of in  vivo murine models is difficult as 
murine malaria parasites do not possess PfEMP1  s [27] 
or knob structures [28] although it has previously been 
shown that Plasmodium berghei infected erythrocytes 
accumulate in the placental tissue of BALB/c mice due to 
low blood flow [29]. Furthermore, a var2csa transgenic P. 
berghei murine placental model has recently been devel-
oped [30]. Plasmodium falciparum infection models in 
Aotus monkeys are currently being developed but they 
are also associated with considerable costs and difficul-
ties. Buffet et  al. described an ex  vivo perfusion model 
utilising human spleen to investigate clearance of drug 
treated P. falciparum infected erythrocytes [31]. In this 
paper, adaptation of a human placental perfusion model 
that replicates natural infected erythrocyte binding to 
intact human placental tissue under flow conditions close 
to the physiological placental flow is described. The dual 
ex  vivo placental perfusion model, where the maternal 
and fetal circulation is re-established in a human placen-
tal cotyledon, has been used extensivley for many years to 
study placental physiology, such as transfer of nutrients 
and IgG across the placental barrier [32, 33]. Placental 
perfusion has shown the role of IgG in mediating mero-
zoite surface protein-1 antigen transfer from mother to 
fetus [34]. The model has also been used to study placen-
tal infections with enterovirus [35] and cytomegalovirus 
[36].
In this study, the modification of the placental perfu-
sion model to study adhesion of malaria parasite-infected 
erythrocytes is described. The model may provide new 
insights into the receptor specificity and availability for 




Parasite isolates were cultured in  vitro as previously 
described [7, 37]. Briefly, parasites were maintained in 
flasks at 5 % haematocrit of human blood group O+ in 
RPMI 1640 HEPES medium supplemented with 25 mM 
NaHCO3, 4  mM  l-glutamine, 0.125  g/l Gentamicin (all 
Sigma-Aldrich), 0.125  g/L Albumax II (Gibco) and 2  % 
human serum. Parasite cultures of the FCR3 and NF54 
genotypes were selected for binding to BeWo cells [38, 
39], which resulted in a parasite culture that expressed 
exclusively VAR2CSA [7] and FCR3 parasite cultures 
were selected for binding to recombinant Endothelial 
Protein C Receptor (EPCR), which resulted in IT4VAR19 
PfEMP1 expression [40]. A transgenic parasite, DC-J, 
in which a PfEMP1 coding region was replaced with a 
drug selectable marker silencing var genes, was used 
as a negative control [41]. PfEMP1 expression in trans-
genic parasites were silenced by addition of 2  µg/ml 
Blasticidin (Gibco). Cultures were kept synchronous by 
repeated enrichment for late stage infected erythrocytes 
Page 3 of 12Pehrson et al. Malar J  (2016) 15:292 
by exposure to a strong magnetic field [42]. Cultures were 
assessed for viability, stage, and parasitaemia by Giemsa-
stained smears, washed and used in the perfusion experi-
ments immediately after preparation or stored at +4  °C 
until used in later phases to prevent schizonts from rup-
turing (up to 9 h).
Parasite cultures were routinely analysed for Myco-
plasma infection and genetic identity of the parasite lines 
was regularly verified by PCR [43, 44].
Ex vivo placental perfusion
The perfusion model was adapted from the models 
described and validated by Schneider et  al. [45] and 
Mathiesen et  al. [46] and the work was initiated by the 
Greifswald perfusion team [47]. Placentas were donated 
by healthy pregnant women undergoing elective caesar-
ean section at term at Copenhagen University Hospital, 
Denmark. Placentas were obtained immediately after 
delivery and Krebs–Ringer buffer with 10  mM glucose 
and 1:9 citrate (Sigma-Aldrich) was injected into the fetal 
arteries. A chorionic artery and vein pair was cannulated 
with neonatal feeding tubes (Flocare) and Krebs–Ringer 
buffer was infused. The perfused cotyledon and sur-
rounding tissue was placed on a holding ring and fixed 
with a clamp. The cotyledon was placed in a heated 
chamber and the fetal and maternal systems were con-
nected to peristaltic roller pumps (Watson Marlow SciQ 
323E/D) to create a flow rate of 3–4 ml/min in the fetal 
circulation and 8–10  ml/min in the maternal circula-
tion (Fig. 1). The maternal circulation was established by 
introduction of three blunted cannulas through the basal 
plate into the intervillous space and venous return was 
continuously drained to the maternal reservoir. Before 
recirculating the fetal and maternal media an open-
loop wash-period was performed. The intervillous space 
was flushed with 300 ml of RPMI 1640 with gentamicin 
0.125  g/l. The media in both circulations were then 
changed and closed-loop perfusion was started. The fetal 
medium was equilibrated with 5  % CO2, 95  % N2. The 
perfusions were performed without addition of gas to the 
maternal medium or with insertion of an oxygenator (liv-
ing systems instrumentation) in the maternal circuit to 
equilibrate the maternal perfusate with atmospheric air.
Oxygen tension, pH, glucose consumption and lactate 
production was analysed every 30  min using an ABL90 
Flex (Radiometer, Denmark). The fetal and maternal per-
fusion medium (100 ml) consisted of RPMI 1640 HEPES 
medium supplemented with 0.125 g/l Gentamicin, human 
serum albumin (CSL Behring) or bovine serum albumin 
(Saveen & Werner AB) 40  mg/ml in the fetal medium 
and 30  mg/ml in the maternal medium [46], and either 
uninfected erythrocytes (human blood group O+) or late 
stage P. falciparum infected erythrocytes at a haematocrit 
of 1 %. A physiological haematocrit was not used due to 
technical difficulties and challenges of culturing para-
sites in large amounts. Before the experimental phases, 
Atmospheric air 





9 5 % N2






Fig. 1 Ex vivo placental perfusion model. After cannulation of a fetal artery and vein pair, the cotyledon is placed in the perfusion chamber with the 
maternal side facing up. Access to the intervillous space is provided by penetration of the decidual plate with three blunt cannulas. The maternal 
perfusate leaves the intervillous space through venous openings and is returned to the maternal circulation through a tube connected to a peristal-
tic pump. The perfusion chamber is surrounded by a water jacket connected to a 37 °C water circuit. The maternal and fetal reservoirs are placed on 
hot magnetic stirrers to ensure a temperature of the perfusate of 37 °C. The fetal perfusate is equilibrated with 95 % N2 and 5 % CO2 which is added 
to the reservoir. An oxygenator inserted into the maternal circulation equilibrates the maternal perfusate with atmospheric air
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a 60  min closed-loop stabilization phase with uninfected 
erythrocytes in both circulations ensured that the tissue 
was intact and viable. Shunts between the fetal and mater-
nal circulation were detected as a decreasing fetal output 
flow rate >0.1 ml/min and resulted in termination of the 
experiment.
Experimental design
To examine whether (1) VAR2CSA expressing parasites 
bind to CSA in an exclusive manner in the placenta and 
(2) whether parasites associated with severe childhood 
malaria (EPCR-binding) accumulate in placental tissue, 
the following experiments were designed:
A: accumulation of VAR2CSA expressing, EPCR bind-
ing and PfEMP1 knockdown parasite in placental tissue: 
The maternal medium was substituted with fresh perfu-
sion medium containing late stage erythrocytes infected 
with FCR3-CSA, FCR3-IT4VAR19 (EPCR binding), 
NF54-CSA or the transgenic DC-J parasite (PfEMP1 
knockdown). After 60  min closed-loop perfusion the 
experiment was terminated.
B: binding inhibition with soluble CSA: The maternal 
medium was substituted with medium containing late 
stage FCR3-CSA expressing erythrocytes pre-incubated 
for 10  min with 800  µg/ml soluble bovine CSA (Fluka). 
After 60 min closed-loop perfusion (Phase 1), the mater-
nal circulation was washed to flush out infected eryth-
rocytes. The maternal medium was changed to fresh 
medium with late stage FCR3-CSA expressing erythro-
cytes and another closed perfusion was performed for 
60 min (Phase 2).
C: binding inhibition with serum: late stage FCR3-
CSA infected erythrocytes were preincubated for 30 min 
with serum from rabbits immunized with full-length 
VAR2CSA (FV2). Pre-incubation of 1 ml parasite culture 
resuspended in RPMI at a total volume of 10 ml was per-
formed at serum concentrations 1:1000, 1:100, and 1:10. 
After pre-incubation albumin and RPMI were added to 
achieve 100 ml perfusion medium. Perfusion experiments 
were performed in four phases separated by a wash phase 
to flush out unbound infected erythrocytes and serum; 
Phase 1: FCR3-CSA without serum, Phase 2: FCR3-CSA 
with anti-FV2 serum 1:1000, Phase 3: FCR3-CSA with 
anti-FV2 serum 1:100, Phase 4: FCR3-CSA with anti-FV2 
serum 1:10 (n = 2) and in the reversed order (n = 3).
During experimental phases, maternal perfusate sam-
ples were collected from the maternal reservoir at 10 min 
intervals.
Protein production
The recombinant full-length VAR2CSA antigen was 
produced essentially as described [48]. Briefly, var2csa 
were made as expression-optimized genes at GeneArt 
(LifeTechnologies). Gene fragments were cloned into 
the baculovirus vector pAcGP67-A (BD Biosciences) 
and used to transfect High five (Life technologies) cells. 
The full length baculo produced protein was purified on 
Ni2+ -sepharose using an ÄKTA-express purification 
system followed by size exclusion. All proteins were qual-
ity controlled by reduced and non-reduced SDS page, 
ELISA and western blot [49, 50].
Immunizations
Full-length VAR2CSA antisera was produced in a New 
Zealand white rabbit by subcutaneous injection of 80 µg 
recombinant VAR2CSA in Freund’s complete adjuvant, 
followed by four booster injections of 40 µg of protein in 
Freund’s incomplete adjuvant. Antisera were collected 
14 days after the final boosting injection.
Flow cytometry
The proportion of infected erythrocytes in the maternal 
circulation was determined by flow cytometry. Perfusate 
was diluted 1:20 in RPMI and stored at 4  °C until ana-
lysed (within 2–10  h). Parasites were labelled with eth-
idium bromide (2  µg/ml) in 100  µl aliquots, incubated 
for 10 min, and washed twice with 200 µl PBS with 2 % 
FCS. Data were acquired using an FC500 flow cytometer 
(Beckman Coulter). All samples from one perfusion were 
processed and analysed together. Data were analysed 
using FlowJo 7.6 by gating on the ethidium bromide posi-
tive cell population and recording the percentage of cells 
relative to the total cell count [51].
Histology
A full-thickness placental biopsy from the perfused coty-
ledon, 1 × 1 × 1 cm, was fixed in 10 % buffered forma-
lin, paraffin embedded, sectioned, mounted on slides and 
haematoxylin-eosin stained. Sections were examined by 
light microscopy at magnification ×60. Infected erythro-
cytes were identified as erythrocytes with coarse brown 
granular material, birefringent in polarized light. On each 
slide, intervillous erythrocytes were counted in 50 fields 
and classified as uninfected erythrocytes, infected eryth-
rocytes in the intervillous space, or infected erythrocytes 
adjacent to the syncytiotrophoblast. Variation in eryth-
rocyte density in the intervillous space within a section 
may reflect variation in circulation dynamics during the 
perfusion. To account for this, parasite density was calcu-
lated as a proportion or per 500 uninfected erythrocytes.
Transmission electron microscopy
Samples from perfused tissue (3 × 3 × 3 mm) were fixed 
for 2 h at room temperature in fixative [1.5 % paraform-
aldehyde (TAAB) and 1.5  % glutaraldehyde (Sigma-
Aldrich) in 0.1  M Sørensen buffer (pH 7.2)], washed in 
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0.1  M Sørensen buffer and stored overnight at 4  °C in 
0.3 M Sørensen buffer. The tissue was immersed in 1 % 
osmium tetroxide for secondary fixation. Samples were 
dehydrated, embedded in Poly/Bed 812® (Polysciences), 
and 50 nm sections were prepared for ultrathin section-
ing on a Leica EM UC7 ultramicrotome. Sections were 
stained with 4  % uranyl acetate and 1  % lead citrate. 
Transmission electron microscopy was performed using 
a Tecnai Spirit Biotwin (FEI Company) microscope.
Scanning electron microscopy
Samples from perfused tissue were excised and fixed as 
described above. After primary fixation, samples were 
dehydrated in increasing concentration of ethanol, criti-
cal point dried (Baltzer CPD030), mounted on stubs, 
sputter coated with chromium (Quorum 150T ES), and 
visualized in a Jeol JSM-7800F at 1 kV.
Ethics approval and consent to participate
All study participants gave informed written con-
sent before donation of their placenta. The study was 
approved by the ethical review board in Capital Region 
of Denmark (reference nr H-1-2012-103). Animal experi-
ments complied with national and international rules for 
vaccination, handling, daily care and welfare. Animals 
were euthanized with fentanyl citrate and fluanisone 
prior to blood sampling and sacrificed with Phenobar-
bital. The study was approved by the Danish Animal 
Experiments Inspectorate (approval number: 2013-
15-2934-00902/BES). The methods were carried out in 
accordance with the approved guidelines for human sub-
jects and experimental animals.
Results
A series of 15 perfusions were performed and several 
steps were taken to optimize the model for perfusion 
with P. falciparum infected erythrocytes (Fig. 1).
Oxygenation
During implementation of the perfusion model the 
maternal perfusate was oxygenated with 20  % CO2, 
80  % O2, as previously described [52], which led to a 
supra-physiological oxygen tension and hemolysis. By 
refraining from oxygenating the maternal perfusate, 
experiments with uninfected and infected erythrocytes 
could be performed. The oxygen tension was approxi-
mately 20–21 kPa after preparation of the perfusate and 
decreased during perfusion as oxygen was consumed 
by the placenta. However, during the 1-h experimental 
phases, maternal oxygen tension rarely fell below that of 
arterial blood. Subsequently, an oxygenator (Living Sys-
tems Instrumentation) was inserted into the maternal 
circulation to equilibrate the maternal perfusate with air, 
which led to more stable oxygen tension. Thus, the perfu-
sions in the dataset below were performed either without 
oxygenation of the maternal perfusate or using an oxy-
genator (Additional file 1).
Coagulation
Heparin has been used during ex  vivo placental perfu-
sion to avoid coagulation before cannulation. However, 
heparin may inhibit the cytoadherence of P. falciparum 
infected erythrocytes [53], therefore, Krebs–Ringer buffer 
with citrate was injected into the fetal arteries immedi-
ately after delivery, and during cannulation and wash of 
the fetal circulation. No anticoagulant was used after the 
wash phase or in the maternal circulation. Initially, the 
volume of the maternal washing medium was 100 ml. In 
these perfusions, remaining maternal blood and clotted 
maternal cannulas were observed. Increasing the volume 
of the washing medium to 300 ml prevented coagulation.
Cryopreserved versus fresh in vitro parasite cultures
For practical reasons, it would be an advantage to use 
cryopreserved late stage parasites [54] for perfusion. 
However, it was technically challenging to thaw the large 
volume of parasites needed within the timeframe of the 
perfusion experiment and to maintain the integrity of a 
high percentage of infected erythrocytes. Thus, for the 
experiments reported here, live cultured parasites were 
used. The use of live cultures complicates the model, as 
the placental perfusion must be performed in close prox-
imity to a laboratory that can maintain high quality para-
site cultures.
Quality parameters
The integrity of the fetal circulation is often assessed by 
monitoring fetal flow rate and loss of fetal perfusate. In 
this study, the focus was on the maternal circulation and 
leakage did not affect parasite adhesion. Caution may be 
necessary in the assessment of fetal flow rate and loss of 
fetal perfusate as variation in flow rate between phases was 
observed, as a result of different colloid osmotic pressure 
in Krebs–Ringer and medium with or without albumin.
After implementation and optimization of the model, 
20 perfusions were performed to test the binding of 
infected erythrocytes. Quality parameters and viability 
characteristics during ex  vivo perfusions are shown in 
Additional file 1.
VAR2CSA expressing P. falciparum infected erythrocytes 
accumulate in ex vivo perfused placental tissue
FCR3 and NF54 parasites were repeatedly selected for 
VAR2CSA expression by binding to BeWo cells. To test 
whether the expression of VAR2CSA enabled bind-
ing in the placenta, infected erythrocytes were perfused 
Page 6 of 12Pehrson et al. Malar J  (2016) 15:292 
through placental tissue. Flow cytometry of perfusate 
samples from the maternal circulation showed that 
FCR3-CSA and NF54-CSA infected erythrocytes disap-
peared from the maternal circulation, indicating that they 
accumulated in the perfused tissue. By contrast, FCR3-
IT4VAR19 (EPCR binding) or DC-J (PfEMP1 silenced) 
infected erythrocytes remained in circulation (Fig.  2). 
The majority of the VAR2CSA expressing parasites disap-
peared from the maternal circulation within 30 min and 
the proportion of infected erythrocytes in the perfusate 
reached a plateau at approximately 15 % of the infected 
erythrocytes injected at t  =  0. There were no binding 
characteristics differences between parasite cultures that 
were used in the perfusion experiment immediately after 
preparation or stored at +4 °C to prevent rupture of schi-
zonts until used in later phases (Additional file 2).
Accumulation of infected erythrocytes in perfused 
tissue was confirmed with light microscopy of haema-
toxylin-eosin stained sections of placental tissue per-
fused with infected erythrocytes. In tissue perfused 
with VAR2CSA expressing parasites, the proportion of 
erythrocytes that were infected increased after 60  min 
perfusion. There was no increase in the proportion of 
infected erythrocytes in tissue perfused with FCR3-
It4var19 infected erythrocytes (Fig. 3a). A large propor-
tion of ex vivo sequestered VAR2CSA expressing infected 
erythrocytes accumulated in the intervillous space rather 
than on the syncytiotrophoblast (Figs. 3b and 4a).
Transmission electron microscopy of FCR3-CSA 
perfused tissue showed interaction between placen-
tal syncytiotrophoblast microvilli and electron dense 
knobs on infected erythrocytes (Fig.  4b–c). Electron 
dense filaments were seen connecting infected erythro-
cytes and syncytiotrophoblast microvilli. Scanning elec-
tron microscopy of FCR3-CSA perfused tissue showed 
infected erythrocytes adhering to the syncytiotropho-
blast surface (Fig. 4 e–f).
Accumulation of infected erythrocytes is inhibited 
by soluble CSA and VAR2CSA specific antibodies
Pre-incubation of VAR2CSA expressing parasites with 
soluble bovine CSA did not block accumulation of 
infected erythrocytes even at high concentration, but 
accumulation was inhibited approximately 50 %, indicat-
ing that placental sequestration of VAR2CSA expressing 
parasites was CSA dependent (Fig. 5).
To evaluate the capacity of the perfusion model to 
measure antibody mediated inhibition of binding, 
infected erythrocytes were pre-incubated with anti-
VAR2CSA antibodies against the full length VAR2CSA. 
A concentration dependent inhibition of binding was 
observed with FV2 specific serum (Fig. 6a–b).
a b
Fig. 2 Accumulation of Plasmodium falciparum infected erythrocytes in ex vivo perfused placental tissue. The figure shows the proportion of 
infected erythrocytes in the perfusate as a function of time. Results from twelve individual perfusion experiments are shown [FCR3-CSA (n = 3), 
FCR3-It4var19 (n = 3), NF54-CSA (n = 3) and DC-J (n = 3)]. The number of infected erythrocytes in the maternal perfusate is expressed as relative 
% of t = 0. a FCR3 parasites expressing VAR2CSA disappear from the circulation while FCR3-It4var19 remain in the maternal circulation. b NF54 
parasites expressing VAR2CSA disappear from the circulation while NF54 parasites that have been silenced for PfEMP1 expression remain in the 
circulation
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Discussion
The existing knowledge of parasite sequestration in pla-
cental malaria originates from field studies and labora-
tory models showing that parasites from pregnant women 
bind to CSA [13], that sera from pregnant women previ-
ously exposed to placental malaria inhibit parasite bind-
ing to CSA [55], that anti-VAR2CSA antibodies are 
predominantly acquired by women exposed to malaria 
during pregnancy and rarely found at high concentration 
in malaria exposed men or children. Moreover, high levels 
of anti-VAR2CSA IgG in pregnant women are associated 
with favourable birth outcomes [8]. The occurrence of 
placental malaria in pregnant women in malaria-endemic 
areas that have developed protective antibodies towards 
a wide array of blood stage antigens during childhood 
underlines the importance of acquiring antibodies, most 
likely anti-adhesive, towards PfEMP1 molecules. Fur-
thermore, binding to receptors other than CSA has been 
associated with placental malaria [17–19]. This could have 
important implications for the etiology of pathology and 
for the development of vaccines that aim to reduce para-
site accumulation in placental tissue. Therefore, an ex vivo 
placental perfusion model was implemented to study par-
asite adhesion in intact placental tissue.
Infected erythrocytes expressing VAR2CSA, of both 
the FCR3 and NF54 genotype, accumulated in the 
perfused tissue, whereas an EPCR binding (FCR3-
IT4VAR19) and a transgenic parasite where PfEMP1 
expression had been silenced (DC-J) did not accumulate 
in the placenta. There was a small loss of It4var19 and 
DC-J infected erythrocytes, which may be explained by 
late stage erythrocyte rupture during the experiment.
These results show that the ex vivo perfusion model is 
suitable to measure placental accumulation of parasites 
and confirm that infected erythrocyte accumulation in 
placental tissue is VAR2CSA specific. Furthermore, as the 
EPCR-binding parasite did not accumulate in placental 
tissue, in spite of expression of EPCR in human placenta 
[56] and on the surface of the syncytiotrophoblast [57], 
it is likely that infected erythrocytes binding to receptors 
other that CSA will not accumulate in placental tissue. 
The exclusive interaction with CSA is possibly conferred 
by shielding of other receptors by the glycocalyx [58]. 
This suggest a minor role for binding to immunoglobulin 
and hyaluronic acid [19, 59, 60], but further studies eluci-
dating the involvement of these receptors in the placental 
perfusion model could shed further light on these obser-
vations. Taken together with the finding that disruption 
of the var2csa gene impairs adherence to syncytiotropho-
blast in vitro [11] the findings in this study imply that a 
vaccine against placental malaria can be limited to target 
only the CSA binding epitope of VAR2CSA.
An advantage of the perfusion model is the oppor-
tunity to study parasite adhesion to intact placental tis-
sue under physiologically relevant flow conditions. The 
details of the flow dynamics of a placental cotyledon 
still remain to be elucidated, but different methods can 
be used to estimate the intervillous flow (see Additional 
file 3 for a discussion). An intervillous flow of 8–10 ml/
min divided on three cannulas to optimize the oxygen 
a
b
Fig. 3 Accumulation of infected erythrocytes in placental tissue. a The bars indicate the percentage of infected erythrocytes in the perfusate at 
t = 0 (black bar) and the percentage of infected erythrocytes in the intervillous space in sections of perfused tissue (grey bar). b The figure shows 
the distribution of infected erythrocytes within the perfused tissue, in the intervillous space (black bars) or adjacent to the syncytiotrophoblast (grey 
bars). The number of infected erythrocytes is expressed relative to 500 uninfected erythrocytes. Shown are results from three individual FCR3-CSA 
perfusions and three FCR3-It4var19 perfusions. Bars represent mean and standard deviation
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erythrocytes bind to a loose matrix of chondroitin sul-
phate proteoglycan chains in the intervillous space [64]. 
Histological examination of the perfused tissue showed 
parasite accumulation both in the intervillous space and 
to a lesser degree on the syncytiotrophoblast, as seen in 
women with placental malaria [65]. Relatively few eryth-
rocytes are seen in the fetal vessels and the intervillous 
space, in perfused tissue compared to non-perfused tis-
sue, as fetal and maternal blood have been washed out 
[66] and due to the low haematocrit of 1  % in the per-
fusion experiments. Transmission electron microscopy 
showed electron dense filaments connecting knobs on 
the infected erythrocyte with syncytiotrophoblast micro-
villi as previously shown in tissue from women with 
placental malaria [67], not limited to denudated areas 
as recently suggested [68]. Moreover, scanning electron 
microscopy showed adherence of infected erythrocytes 
to intact syncytiotrophoblast.
This proof of concept study could form the basis of 
studying placental pathology in native tissue. How-
ever, close collaboration with a labor ward is necessary, 
Fig. 4 Adhesion of Plasmodium falciparum infected erythrocytes in ex vivo perfused placental tissue. a Haematoxylin eosin stained section of 
placental tissue perfused with FCR3-CSA (magnification × 60). Infected erythrocyte accumulation in the intervillous space (open arrow) and on the 
syncytiotrophoblast (closed arrows) is shown. b Transmission electron micrograph of an FCR3-CSA infected erythrocyte in the intervillous space 
adjacent to syncytiotrophoblast microvilli (arrow) on both sides. c Magnification of b showing filamentous material connecting a knob on the 
infected erythrocyte (star) and a syncytiotrophoblast microvillus (arrow). d Scanning electron micrograph of the villous tree showing the complex 
architecture through which the maternal blood flows. e, f. Scanning electron micrographs showing VAR2CSA expressing infected erythrocytes 
adhering to syncytiotrophoblast
delivery to the cotyledon is estimated to be within the 
physiological range. Methodological studies investigating 
the effect of increasing the number of maternal cannulas 
and the flow rate during ex vivo placental perfusion have 
been performed [61, 62]. Increased spiral artery veloc-
ity may impair maternal-fetal exchange and damage the 
villous tissue [63] and was associated with morphologi-
cal damage of the syncytiotrophoblast in the perfusion 
model [62]. Although replicating the physiological flow 
in the perfusion model is a challenge, a flow is created 
where the maternal perfusate percolates the villous tree 
at a pressure gradient from the maternal cannulas to the 
outflow through the basal plate thus simulating the inter-
villous blood flow. This is an advantage compared to pla-
cental malaria models using a capillary or chamber flow 
system without the villous tree.
Another advantage of the perfusion model is that the 
intervillous space of the placenta is intact and unfixed 
so that adherence of infected erythrocytes, not only 
to the syncytiotrophoblast, but also in the intervillous 
space, can be studied. It has been suggested that infected 
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as placentas must be accessed immediately after deliv-
ery and brought to the laboratory for processing within 
a short period of time. Moreover, it is imperative that 
stable and well-characterized PfEMP1 phenotypes are 
established prior to generating the amounts required 
for the perfusion experiments. Still, the perfusion group 
in Greifswald performed pilot experiments, suggesting 
that the model is indeed transferrable between different 
centres.
Adhesion of VAR2CSA expressing parasites was inhib-
ited, but not blocked completely by soluble CSA. It has 
recently been shown that placental chondroitin sul-
fate shares a specific signature with chondroitin sulfate 
expressed on cancer cells, which is not found in other 
healthy human tissues [23]. The incomplete binding inhi-
bition may be caused by differences in parasite tropism 
for bovine CSA and the human oncofetal CSA found in 
the placenta.
Antibodies against the full-length VAR2CSA pro-
tein inhibited parasite binding in placental tissue in a 
concentration dependent manner. Some variation was 
seen between experiments and the binding inhibition 
appeared greater when the experiments where performed 
with increasing concentrations of serum compared to the 
reversed order. One explanation could be that infected 
Fig. 5 Soluble CSA inhibit FCR3-CSA infected erythrocyte acculmula-
tion in perfused tissue. The Figure shows the proportion of infected 
erythrocytes in the perfusate as a function of time. Three individual 
perfusion experiments (indicated by circle, square or triangle) with 
FCR3-CSA incubated with soluble bovine CSA in Phase 1 (solid line) 
and FCR3-CSA in Phase 2 (dotted line). Soluble bovine CSA partly 
inhibits accumulation of FCR3-CSA in perfused placental tissue
Fig. 6 VAR2CSA specific antibodies inhibit FCR3-CSA infected erythrocyte acculmulation in perfused tissue. a Serum from a rabbit immunized with 
the full-length VAR2CSA protein in increasing concentrations inhibits binding of VAR2CSA expressing infected erythrocytes in perfused tissue (repre-
sentative of two experiments). b Serum against FV2 as in a but in decreasing concentration (representative of three experiments)
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erythrocytes that had adhered in the placenta during pre-
vious phases were released when a higher concentration 
of serum was perfused through the tissue. This is a weak-
ness of the model, which needs to be investigated further 
as it affects the ability to quantify the inhibition capacity 
if experiments are run in several phases.
Conclusions
This proof of concept study show that VAR2CSA express-
ing infected erythrocytes accumulate in the ex vivo pla-
cental perfusion model with a distribution similar to that 
seen in natural placental infection. Parasite accumula-
tion is inhibited by soluble CSA and anti-VAR2CSA anti-
bodies. In conclusion, the perfusion model bestows an 
opportunity to study parasite binding biology in intact 
human tissue and the functional properties of antibodies 
from both pre-clinical and clinical trials.
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